Mesna
(Redirected from Mistabronco)
What is Mesna?[edit | edit source]
- Mesna (Mesnex) is a cytoprotective agent used to prevent hemorrhagic cystitis (bleeding in the bladder) caused by the anticancer drug ifosfamide.
What are the uses of this medicine?[edit | edit source]
- Mesna (Mesnex) is a prescription medicine used to reduce the risk of inflammation and bleeding of the bladder (hemorrhagic cystitis) in people who receive ifosfamide (a medicine used to treat cancer).
Limitation of Use:
- Mesnex is not for use to reduce the risk of blood in the urine (hematuria) due to other medical conditions.
How does this medicine work?[edit | edit source]
- Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification.
- The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide.
- Mesna also binds to the double bonds of acrolein and to other urotoxic metabolites and inhibits their effects on the bladder.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients who:
- are allergic to mesna or any of the ingredients in Mesnex.
What drug interactions can this medicine cause?[edit | edit source]
- Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
Is this medicine FDA approved?[edit | edit source]
- Mesna was approved for medical use in the United States in 1988.
How should this medicine be used?[edit | edit source]
Recommended dosage:
- Mesnex may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of Mesnex tablets as below:
Intravenous Dosing Schedule:
0 Hours | 4 Hours | 8 Hours | |
---|---|---|---|
Ifosfamide | 1.2 g/m2 | - | - |
Mesnex injection | 240 mg/m2 | 240 mg/m2 | 240 mg/m2 |
Intravenous and Oral Dosing Schedule:
0 Hours | 2 Hours | 6 Hours | |
---|---|---|---|
Ifosfamide | 1.2 g/m2 | - | - |
Mesnex injection | 240 mg/m2 | - | - |
Mesnex tablets | - | 480 mg/m2 | 480 mg/m2 |
Administration:
- Mesnex is given on the same day that you receive ifosfamide.
- Mesnex can be given by an intravenous (IV) infusion into a vein or tablets taken by mouth.
You will receive Mesnex in one of two ways:
- Mesnex intravenous (IV) infusion into a vein at the time you receive ifosfamide and 4 and 8 hours after you receive ifosfamide, OR
- Mesnex intravenous (IV) infusion into a vein at the time you receive ifosfamide and Mesnex tablets taken by mouth 2 and 6 hours after you receive ifosfamide.
- Take Mesnex tablets at the exact times and the exact dose your healthcare provider tells you to take it.
- During treatment with Mesnex intravenous (IV) infusion or Mesnex tablets, you should drink 4 to 8 cups of liquid (1 to 2 liters) each day.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Injection: 1g (100 mg/mL) Multidose vials
- Tablets: 400 mg with functional score
This medicine is available in fallowing brand namesː
- Mesnex
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- nausea
- vomiting
- constipation
- decreased white blood cell count
- tiredness
- fever
- decreased appetite
- decreased platelet count
- decreased red blood cell count
- diarrhea
- weakness
- stomach (abdomen) pain
- headache
- hair loss
- sleepiness
Mesnex may cause serious side effects, including:
- serious allergic reactions and skin reactions
What special precautions should I follow?[edit | edit source]
- Mesnex may cause systemic hypersensitivity reactions, including anaphylaxis. Anaphylactic reactions have been reported. Less severe hypersensitivity reactions may also occur. Monitor patients. If a reaction occurs, discontinue Mesnex and provide supportive care.
- Skin rash with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis have occurred. Skin rash, urticaria, and angioedema have also been seen. Monitor patients. If a reaction occurs, discontinue Mesnex and provide supportive care.
- Serious and fatal adverse reactions can occur in premature neonates and low-birth weight infants treated with benzyl alcohol-preserved drugs, including Mesnex injection. Avoid use in premature neonates and low-birth weight infants.
- False positive tests for urinary ketones and interference with enzymatic CPK activity tests have been seen.
- Mesnex is a thiol compound, i.e., a sulfhydryl (SH) group-containing organic compound. Hypersensitivity reactions to mesna and to amifostine, another thiol compound, have been reported.
What to do in case of emergency/overdose?[edit | edit source]
Symptoms of overdosage may include:
- nausea
- vomiting
- diarrhea
- fever
- hypotension
- shortness of breath
- asthma exacerbation
- rash
- flushing
Management of overdosage:
- There is no known antidote for Mesnex.
- In the event of an overdose, appropriate supportive treatment should be initiated.
Can this medicine be used in pregnancy?[edit | edit source]
- Mesnex is used in combination with ifosfamide or other cytotoxic agents.
- Ifosfamide can cause fetal harm when administered to a pregnant woman.
Can this medicine be used in children?[edit | edit source]
- Mesnex injection contains the preservative benzyl alcohol which has been associated with serious adverse reactions and death when administered intravenously to premature neonates and low birth weight infants.
- Avoid use of Mesnex injection in premature neonates and low-birth weight infants.
What are the active and inactive ingredients in this medicine?[edit | edit source]
Active ingredient: mesna
Inactive ingredients:
- Mesnex injection: edetate disodium, sodium hydroxide, and benzyl alcohol as a preservative.
- Mesnex tablets: calcium phosphate, cornstarch, hydroxypropylmethylcellulose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, simethicone, and titanium dioxide.
Who manufactures and distributes this medicine?[edit | edit source]
Manufactured by:
- Baxter Healthcare Corporation, Deerfield, IL USA
- Made in Germany
- Baxter and Mesnex are registered trademarks of Baxter International Inc.
What should I know about storage and disposal of this medication?[edit | edit source]
- Store Mesnex tablets at room temperature between 68°F to 77°F (20°C to 25°C).
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju